GO2 for Lung Cancer announced that researchers have described a new familial syndrome in people with lung cancer caused by an inherited gene mutation. The research study was published this month in the Journal of Clinical Oncology. The report chronicles [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people [...]
JoAnn Berridge was misdiagnosed, repeatedly. Doctors thought she had allergy-related post-nasal drip; then they thought she had acid reflux. After a year of trial and error and a persistent cough, her primary care physician ordered a chest X-ray in [...]
On September 15th, 2021, the Food and Drug Administration (FDA) approved Exkivity (mobocertinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results [...]
Activist urges participation to crack the code. Jill Feldman with family Jill Feldman is passionate about advocating for lung cancer research. A mother of 4 young children, she was diagnosed at age 39 with EGFR positive lung [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso [...]
On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of [...]